ArticleCancer immunology, immunotherapy : CII2025
A multifunctional T-cell engager containing CD80 enhances prostate cancer treatment.
Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundT-cell engagers (TCEs), the most extensively studied class of bispecific antibodies, redirect effector T cells to tumor cells to induce immune synapse formation, T-cell activation, and subsequent tumor cell killing. However, their therapeutic efficacy in solid tumors is limited by immunosuppressive mechanisms within the tumor microenvironment (TME). To address this challenge, we engineered an enhanced PSMA/CD3 bispecific antibody by incorporating the extracellular domain of CD80, which provides a co-stimulatory signal to counteract T-cell inhibition in prostate cancer. This trifunctional antibody is designated as TriTE-N13.
methodsWe engineered the fully humanized fusion antibody TriTE-N13 using gene editing and eukaryotic expression systems. In vitro, we evaluated its ability to activate and proliferate T cells, as well as its cytotoxicity against PSMA
resultsIn vitro, TriTE-N13 demonstrated robust activation of human T cells and high-affinity binding to both human PSMA and CD3 antigens. Furthermore, TriTE-N13 effectively mediated T-cell-dependent cytotoxicity against PSMA-positive prostate cancer cells. In vivo studies revealed that TriTE-N13 achieved significantly greater tumor volume reduction compared to conventional bispecific TCEs, particularly in established large tumors.
conclusionsOur findings indicate that incorporating CD80 as a co-stimulatory signal substantially enhances the antitumor efficacy of TCEs against solid tumors. These results position TriTE-N13 as a promising immunotherapeutic candidate for advanced prostate cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.